Skip to content
Precision for Medicine
iStock-1148211446

Multiplex Cytokine Assays with Luminex®

Cytokine levels can provide important insight into immunological events within a sample

At Precision, we utilize several technologies for cytokine analysis, including the Luminex platform for multiplex cytokine assays.

Luminex has advantages of high sensitivity while requiring low sample input and rapid analysis.

Build a complete understanding of the cytokines present in your sample

Our standard assays are designed to measure cytokines and chemokines released from chosen target cells, and we specialize in activated T-cell–based assays requiring same-day treatment and processing. All of our assays can be customized to detect specific groups of cytokines.

Advantages of Luminex assays

The Luminex platform uses fluorescently-labeled beads bound to capture antibodies to quantitatively detect a specific cytokine or other analyte of interest.

  • Multiplex up to 50-100 analytes
  • Wide dynamic range
  • High sensitivity
  • Low sample input
  • Limited matrix interference
  • Rapid analysis (a single 96-well plate run can be completed in just 60 minutes)
  • Commercially available panels and custom panels
  • An ideal choice for research and exploratory purposes

Our Luminex capabilities

  • Assay development or transfer, validation, and implementation
  • Prebuilt or custom Luminex assays
  • Integration with Precision’s other bioanalytical and specialty assays and technlogies
Specialty_QuartzBio

Resources related to protein and cytokine analysis 

Explore all resources

Additional cytokine and protein profiling services

  • Explore
    PBMC-processing_card-thumbnail

    ELISA

    Services using the gold standard for quantitative antibody-based bioanalysis, with specialization in immunogenicity assay development
    Explore

    ELISA

    Services using the gold standard for quantitative antibody-based bioanalysis, with specialization in immunogenicity assay development
    Explore
  • Explore

    Olink Proteomics

    High-multiplex quantification of protein biomarkers with minimal clinical sample volume and exceptional sensitivity and specificity
    Explore

    Olink Proteomics

    High-multiplex quantification of protein biomarkers with minimal clinical sample volume and exceptional sensitivity and specificity
    Explore

Explore the Precision blog

Read our blog to gain more insights and discover work that Precision has supported.

Read: Receptor Occupancy in the Era of Multispecific Therapeutics Receptor Occupancy in the Era of Multispecific Therapeutics

Translational Research - Lab Services

Receptor Occupancy in the Era of Multispecific Therapeutics

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778875, hs_child_table_id=0, hs_updated_at=1716454216458, hs_published_at=1785476963368, description=Pharma industry veteran and expert at biomarker-driven clinical trial design and execution. Leader of biomarker and drug development programs for pharmaceutical and diagnostics companies, as well as the National Institutes of Health. Spearheaded the discovery of pharmacodynamic biomarkers and novel targets for inflammatory disease therapy., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Deb%20Phippard.webp',altText='Deb Phippard',fileId=165892372605}, linkedin=https://www.linkedin.com/in/deb-phippard-103b54, team=[{id=163072475007, name='Precision for Medicine Leadership'}], hs_name=, hs_path=, lastname=Phippard, PhD, hs_initial_published_at=1775839468505, hs_created_at=1709645745106, hs_is_edited=false, hs_deleted_at=0, name=Deborah, job= Chief Scientific Officer, slug=deborah-phippard, email=, hs_updated_by_user_id=65160865}, second={hs_id=218178874459, hs_child_table_id=0, hs_updated_at=1785241362455, hs_published_at=1785476963368, description=Jenny Zilberberg has more than 20 years of combined experience across academia and biotechnology, with expertise in translational immunology, cancer immunotherapy, and biomarker strategy. Most recently, she served as Head of Research at Imvax, where she led preclinical development and biomarker activities for the company’s immunotherapy platform and lead glioblastoma program. At Precision, Jenny partners with sponsors to design and implement biomarker and bioanalytical solutions that support clinical development across oncology and autoimmune diseases., avatar=Image{width=480,height=480,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/JennyZilberberg.jpeg',altText='JennyZilberberg',fileId=218182303073}, lastname=Zilberberg, hs_initial_published_at=1785241367324, hs_created_by_user_id=65712240, hs_created_at=1785241302354, hs_is_edited=false, hs_deleted_at=0, name=Jenny, job=Vice President, Scientific Strategy, slug=Jenny-zilberberg, hs_updated_by_user_id=65160865}, third={}})
  • Deborah P. avatar

    Deborah P.

  • Jenny Z. avatar

    Jenny Z.

Discover
Read: Developing a Comprehensive Strategy for Implementing AI & Multi-Omics for Translational Research Developing a Comprehensive Strategy for Implementing AI & Multi-Omics for Translational Research

Translational Research

Developing a Comprehensive Strategy for Implementing AI & Multi-Omics for Translational Research

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=199448088864, hs_child_table_id=0, hs_updated_at=1762810484868, hs_published_at=1785476963368, avatar=Image{width=1200,height=1200,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Kaylee%20Mueller.png',altText='Kaylee Mueller',fileId=199456336149}, lastname=Mueller, hs_initial_published_at=1762810487482, hs_created_by_user_id=26433386, hs_created_at=1762810467146, hs_is_edited=false, hs_deleted_at=0, name=Kaylee, slug=kaylee-mueller, hs_updated_by_user_id=65160865}, second={}, third={}})
  • Kaylee Mueller avatar

    Kaylee Mueller

Discover
Read: Back to the Source: A Translational Leader on Extending the Living Legacy of Genomic Data Back to the Source: A Translational Leader on Extending the Living Legacy of Genomic Data

Translational Research - Biospecimens - Oncology

Back to the Source: A Translational Leader on Extending the Living Legacy of Genomic Data

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778886, hs_child_table_id=0, hs_updated_at=1763657611624, hs_published_at=1785476963368, description=Robert Snyder, PhD, is a seasoned expert with a 20-year track record in genomics, specializing in in vitro diagnostic assay development and bioinformatics. Committed to advancing medical science, he is proficient in regulatory V&V study designs and understands the nuances of orthogonal methods. A collaborative partner in biomedical development, Dr. Snyder champions the critical transition of biospecimens from benchtop to bedside., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Robert%20Snyder.webp',altText='Robert Snyder',fileId=165892444501}, linkedin=https://www.linkedin.com/in/robert-snyder-ph-d-9b67b035, hs_name=, hs_path=, lastname=Snyder, PhD, hs_initial_published_at=1775839468505, hs_created_at=1709645745117, hs_is_edited=false, hs_deleted_at=0, name=Robert, job=, slug=robert-snyder, email=, hs_updated_by_user_id=65160865}, second={}, third={}})
  • Robert Snyder, PhD avatar

    Robert Snyder, PhD

Discover